Calamos Advisors LLC Has $41.53 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Calamos Advisors LLC grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 34.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 123,108 shares of the medical equipment provider's stock after purchasing an additional 31,249 shares during the period. Calamos Advisors LLC's holdings in Intuitive Surgical were worth $41,532,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. AIA Group Ltd boosted its stake in shares of Intuitive Surgical by 19.4% during the 4th quarter. AIA Group Ltd now owns 12,999 shares of the medical equipment provider's stock worth $4,385,000 after acquiring an additional 2,108 shares in the last quarter. SFE Investment Counsel lifted its stake in Intuitive Surgical by 6.2% in the 4th quarter. SFE Investment Counsel now owns 1,412 shares of the medical equipment provider's stock valued at $476,000 after buying an additional 83 shares in the last quarter. Oliver Lagore Vanvalin Investment Group lifted its stake in Intuitive Surgical by 71.1% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 3,694 shares of the medical equipment provider's stock valued at $1,246,000 after buying an additional 1,535 shares in the last quarter. Federated Hermes Inc. lifted its stake in Intuitive Surgical by 54.9% in the 4th quarter. Federated Hermes Inc. now owns 242,094 shares of the medical equipment provider's stock valued at $81,673,000 after buying an additional 85,843 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its stake in Intuitive Surgical by 74.6% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 840 shares of the medical equipment provider's stock valued at $283,000 after buying an additional 359 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Mizuho upped their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a "neutral" rating in a research note on Thursday, January 25th. Piper Sandler upped their target price on Intuitive Surgical from $325.00 to $425.00 and gave the company an "overweight" rating in a research note on Wednesday, January 24th. Wells Fargo & Company upped their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an "overweight" rating in a research note on Friday, January 19th. Royal Bank of Canada upped their target price on Intuitive Surgical from $400.00 to $432.00 and gave the company an "outperform" rating in a research note on Wednesday, January 24th. Finally, Truist Financial upped their target price on Intuitive Surgical from $390.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $375.70.

Insider Activity at Intuitive Surgical

In related news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the sale, the director now directly owns 25,319 shares in the company, valued at approximately $9,373,093.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the company's stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares of the company's stock, valued at approximately $9,373,093.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Myriam Curet sold 4,318 shares of the stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the transaction, the executive vice president now directly owns 189 shares in the company, valued at approximately $69,958.35. The disclosure for this sale can be found here. In the last three months, insiders sold 248,418 shares of company stock worth $95,927,097. Corporate insiders own 0.90% of the company's stock.

Intuitive Surgical Price Performance

NASDAQ ISRG traded down $1.54 during trading hours on Thursday, hitting $372.63. The company had a trading volume of 2,312,736 shares, compared to its average volume of 1,644,831. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The company has a market capitalization of $132.08 billion, a price-to-earnings ratio of 74.08, a P/E/G ratio of 5.88 and a beta of 1.36. The firm's 50 day moving average is $387.27 and its 200 day moving average is $342.60.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the prior year, the firm earned $1.00 EPS. The firm's quarterly revenue was up 11.5% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.